Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Merck KGaA licenses Hengrui cancer drug candidates

by Laura Howes
November 9, 2023 | A version of this story appeared in Volume 101, Issue 37

 

Merck KGaA has signed a deal with the Chinese firm Jiangsu Hengrui Pharmaceuticals to bring to market two of Hengrui’s oncology drugs: HRS-1167, a PARP1 inhibitor, and SHR-A1904, an antibody-drug conjugate. For $169 million up front, Merck gets the rights to both drugs outside China. Merck says that the acquisition of HRS-1167 aligns with its in-house expertise in DNA damage response. The firm is exploring whether the inhibitor could be combined with other drugs for maximum effect.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.